Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;48(2):e74-e75.
doi: 10.1111/1346-8138.15638. Epub 2020 Oct 9.

Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis

Takuya Furuhashi  1 , Takao Oda  2 , Kan Torii  2 , Emi Nishida  2 , Akimichi Morita  2
Affiliations

Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis

Takuya Furuhashi et al. J Dermatol. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
(a,b) Comparison of transepidermal water loss (TEWL) and stratum corneum hydration (SCH) between atopic dermatitis (AD) patients (Pt) and age‐matched controls (n = 7). Each site was measured three times, and the mean was used for analysis (Student’s t‐test). (c,d) Changes in TEWL and SCH levels in the lesions (hand, forehead, forearm anterior, forehead, cheek and forehead). Analyses were performed with two‐way anova and Dunnett’s test. (e) Changes in TEWL levels in six sites from the index date to 24 weeks. Analyses were performed with two‐way anova and Dunnett’s test. (f) Changes in SCH levels in six sites from the index date to 24 weeks.
See this image and copyright information in PMC

References

    1. Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018; 78: S28–S36. - PubMed
    1. Cork MJ, Thaçi D, Eichenfield LF et al Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a Phase IIa open‐label trial and subsequent phase III open‐label extension. Br J Dermatol 2020; 182: 85–96. - PMC - PubMed
    1. Paller AS, Siegfried EC, Thaçi D et al Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double‐blinded, placebo‐controlled Phase 3 trial. J Am Acad Dermatol 2020; 10.1016/j.jaad.2020.06.054 - DOI - PubMed
    1. Ho CJH, Yew YW, Dinish US et al Handheld confocal Raman spectroscopy (CRS) for objective assessment of skin barrier function and stratification of severity in atopic dermatitis (AD) patients. J Dermatol Sci 2020; 98: 20–25. - PubMed
    1. Kabashima K, Matsumura T, Komazaki H et al Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141–150. - PubMed